Valproate Treatment in an ALS Patient Carrying a c.194G>A Spastin Mutation and SMN2 Homozygous Deletion
Here we report the case of an ALS patient found to carry both a novel heterozygous change (c.194G>A) within the spastin gene and a homozygous deletion of the SMN2 gene. The patient was started on valproic acid (VPA, 600 mg/die per os) considering the capacity of this drug of increasing survival m...
Main Authors: | Lucio Tremolizzo, Gessica Sala, Elisa Conti, Virginia Rodriguez-Menendez, Antonella Fogli, Angela Michelucci, Paolo Simi, Silvana Penco, Christian Lunetta, Massimo Corbo, Carlo Ferrarese |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | Case Reports in Neurological Medicine |
Online Access: | http://dx.doi.org/10.1155/2014/216094 |
Similar Items
-
Association between the SMN2 gene copy number and clinical characteristics of patients with spinal muscular atrophy with homozygous deletion of exon 7 of the SMN1 gene
by: Žarkov Marija, et al.
Published: (2015-01-01) -
Spastin's microtubule-binding properties and comparison to katanin.
by: Thomas Eckert, et al.
Published: (2012-01-01) -
Expression of recombinant mouse spastin in E. coli
by: Wang Yujuan
Published: (2020-01-01) -
Der Einfluss von R-Roscovitine und Valproat auf das Wachstums- und präsynaptische Differenzierungsverhalten SMN-defizienter Motoneurone
by: Drexl, Hans Henning
Published: (2018) -
Sialorrhoea: How to Manage a Frequent Complication of Motor Neuron Disease
by: Andrea Pellegrini, et al.
Published: (2015-08-01)